Very short-term effects of a single dose of a proprotein convertase subtilisin/kexin 9 inhibitor before percutaneous coronary intervention: A single-arm study

Atherosclerosis. 2024 Dec:399:118581. doi: 10.1016/j.atherosclerosis.2024.118581. Epub 2024 Sep 2.

Abstract

Background and aims: The short-term (within 6 weeks) effects of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on lipid plaques have not been adequately evaluated. We aimed to investigate whether a single dose of a PCSK9 inhibitor before percutaneous coronary intervention (PCI) could reduce the abundance of lipid-core plaques identified via near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) at target lesions within a very short period.

Methods: This prospective, single-arm, single-center interventional study enrolled 27 consecutive patients with coronary artery disease. These patients underwent NIRS-IVUS during coronary angiography and repeat NIRS-IVUS during PCI performed between 2 and 6 weeks after the single-dose administration of 420 mg evolocumab. Changes in lesion lipid-core burden index (LCBI) and maximal LCBI over any 4-mm segment (max-LCBI4mm) were assessed using NIRS at the target lesions, along with lipid profile.

Results: The max-LCBI4mm significantly decreased from 387 before PCSK9 inhibitor administration to 315 after its administration (interquartile range [IQR]: 268-572 and 221-488, respectively; p = 0.02) within a very short period. The lesion LCBI also decreased from 161 to 117 (IQR: 105-263 and 65-226, respectively; p = 0.02). No significant changes were observed in the minimum lumen area and diameter. After PCSK9 inhibitor administration, low-density lipoprotein (LDL) cholesterol (p < 0.001), lipoprotein(a) (p = 0.001), and malondialdehyde-modified LDL (p < 0.001) levels decreased compared with those before its administration.

Conclusions: A single dose of the PCSK9 inhibitor administered before PCI reduced the abundance of lipid-core plaques identified via NIRS-IVUS at target lesions within a very short period of 2-6 weeks.

Keywords: Coronary artery disease; Maximal lipid-core burden; Near-infrared spectroscopy intravascular ultrasound; Proprotein convertase subtilisin/kexin 9 inhibitor; lipoprotein(a).

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / therapeutic use
  • Biomarkers / blood
  • Cholesterol, LDL / blood
  • Coronary Angiography*
  • Coronary Artery Disease* / diagnostic imaging
  • Coronary Artery Disease* / therapy
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / drug effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • PCSK9 Inhibitors*
  • Percutaneous Coronary Intervention* / adverse effects
  • Plaque, Atherosclerotic*
  • Proprotein Convertase 9 / metabolism
  • Prospective Studies
  • Serine Proteinase Inhibitors / administration & dosage
  • Serine Proteinase Inhibitors / adverse effects
  • Serine Proteinase Inhibitors / therapeutic use
  • Spectroscopy, Near-Infrared*
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Interventional*

Substances

  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • evolocumab
  • Antibodies, Monoclonal, Humanized
  • Serine Proteinase Inhibitors
  • Proprotein Convertase 9
  • Cholesterol, LDL
  • Biomarkers
  • Anticholesteremic Agents